Skip to main content

Table 2 Subgroup analyses reflecting the association between tumor length and OS in EC patients

From: Prognostic impact of tumor length in esophageal Cancer: a systematic review and Meta-analysis

 

Random-effects model

 

Fixed-effects model

   

Subgroup

No. of studies

HR (95% CI)

P

HR (95% CI)

P

I2 (%)

Ph

Overall

35

1.301 (1.210–1.399)

<.001

1.151 (1.117–1.185)

<.001

66.8%

<.001

Patient source

 China

23

1.290 (1.191–1.397)

<.001

1.155 (1.117–1.195)

<.001

64.6%

<.001

 Japan

6

1.540 (1.108–2.142)

.010

1.446 (1.174–1.781)

<.001

47.0%

.093

 US

5

1.457 (0.851–2.495)

.170

1.288 (1.046–1.586)

.017

84.1%

<.001

 The Netherlands

1

1.080 (1.008–1.157)

.029

1.080 (1.008–1.157)

.029

–

–

 Italy

1

1.258 (0.890–1.778)

.193

1.283 (1.001–1.644)

.049

–

–

Histology

 SCC

28

1.332 (1.227–1.445)

<.001

1.163 (1.125–1.203)

<.001

64.0%

<.001

 AC

3

1.616 (0.950–2.748)

.077

1.469 (1.103–1.957)

.009

67.9%

.044

 Mixed

5

1.128 (0.895–1.421)

.307

1.095 (1.029–1.166)

.004

78.5%

.001

Treatment

 Surg2

24

1.311 (1.207–1.423)

<.001

1.127 (1.091–1.165)

<.001

67.3%

<.001

 Others

11

1.270 (1.066–1.514)

.007

1.250 (1.170–1.336)

<.001

59.5%

.006

Sample size

  ≤ 200

16

1.458 (1.245–1.707)

<.001

1.163 (1.098–1.233)

<.001

56.3%

.003

  > 200

19

1.264 (1.157–1.380)

<.001

1.146 (1.108–1.186)

<.001

73.3%

<.001

Median age

  < 60

9

1.422 (1.228–1.647)

<.001

1.124 (1.071–1.179)

<.001

74.5%

<.001

  ≥ 60

14

1.281 (1.132–1.450)

<.001

1.133 (1.083–1.185)

<.001

67.5%

<.001

Cut-off value

  < 5 cm

21

1.322 (1.210–1.443)

<.001

1.123 (1.086–1.162)

<.001

67.9%

<.001

  ≥ 5 cm

14

1.259 (1.096–1.446)

.001

1.241 (1.169–1.317)

<.001

59.4%

.002

LN metastasis (% of total)

  < 50%

13

1.351 (1.189–1.537)

<.001

1.106 (1.061–1.153)

<.001

73.9%

<.001

  ≥ 50%

18

1.281 (1.162–1.413)

<.001

1.194 (1.144–1.246)

<.001

62.3%

<.001

TNM stage III/IV (% of total)

  < 50%

12

1.441 (1.240–1.676)

<.001

1.377 (1.245–1.524)

<.001

44.5%

.062

  ≥ 50%

14

1.243 (1.088–1.421)

.001

1.190 (1.134–1.249)

<.001

69.5%

<.001

HR estimate

 UV

16

1.676 (1.469–1.914)

<.001

1.218 (1.180–1.256)

<.001

91.3%

<.001

 MV

35

1.301 (1.210–1.399)

<.001

1.151 (1.117–1.185)

<.001

66.8%

<.001

  1. HR hazard ratio, CI confidence interval, Ph P value of Q test for heterogeneity test, SCC squamous cell carcinoma, AC adenocarcinoma; UVA univariate analysis, MVA multivariate analysis, LN lymph node, Surg2 Surg±Adj CRT
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us